Clinical trials: Hypergastrinaemia
Hypergastrinaemia
Effect of Single Doses of YF476 on Stomach Acidity
The objective of the study was to assess the effect of a range of single oral doses of YF476 on pentagastrin-induced gastric acid output in healthy volunteers
- Trial name
- NCT01601418
- Testing
- YF476
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Barrett's Esophagus
YF476 in Barrett's Esophagus
A phase 2, randomised, double-blind, out-patient trial to determine if YF476 is a safe and effective treatment in patients with Barrett's esophagus.
- Trial name
- NCT02597712
- Testing
- YF476
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Trio Medicines Ltd.
Chronic Atrophic Gastritis, Hypergastrinaemia
YF476 and Type I Gastric Carcinoids
The aim of the study is to find out if the experimental medicine, YF476, can make gastric carcinoids, a rare type of stomach tumour, shrink and disappear.
- Conditions
- Chronic Atrophic Gastritis, Hypergastrinaemia, Type I Gastric Carcinoids
- Trial name
- NCT01339169
- Testing
- YF476
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Trio Medicines Ltd.
Hypergastrinaemia
Effects of YF476 and Rabeprazole on Gastric Function
The primary objectives are to find out in healthy subjects if: YF476 prevents the ECL-cell hyperplasia induced by repeated doses of rabeprazole - a proton pump inhibitor; YF476 also prevents rebound hyperacidity after stopping…
- Trial name
- NCT01699113
- Testing
- YF476, Rabeprazole
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Hypergastrinaemia
Effect of Repeated Doses of YF476 on Stomach Acidity
The objectives of the study were: 1. To show that a single dose of YF476 blocks gastrin receptors in healthy subjects 2. To show that YF476 retains its ability to block gastrin receptors after repeated dosing despite losing its…
- Trial name
- NCT01601405
- Testing
- YF476
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Chronic Atrophic Gastritis, Hypergastrinemia
YF476 and Type I Gastric Carcinoids (Norway)
The aim of the study is to find out if the experimental medicine, YF476, can make gastric carcinoids, a rare type of stomach tumour, shrink and disappear.
- Conditions
- Chronic Atrophic Gastritis, Hypergastrinemia, Type I Gastric Carcinoids
- Trial name
- NCT01444014
- Testing
- YF476
- Where
- Norway
- Volunteers
- 8 people
- Sponsor
- Trio Medicines Ltd.